Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
September 02 2020 - 8:00AM
Business Wire
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM)
(“Aptorum Group”), a biopharmaceutical company focused on novel
therapeutics including the development of next-generation approach
therapeutics targeting antimicrobial resistance, announced its
President and Executive Director, Darren Lui, provided a video
update to further discuss the Company’s recent news about further
positive data from its latest in vivo studies showing significant
activity against neuroblastoma tumor reduction when treated with
its lead compound SACT-1 in combination with standard of care (SOC)
chemotherapy.
To view the video, please visit:
https://youtu.be/YYWqYI6Y2rA
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a
pharmaceutical company dedicated to developing and commercializing
novel therapeutics to tackle unmet medical needs. Aptorum Group is
pursuing therapeutic projects in orphan diseases, infectious
diseases, metabolic diseases, woman’s health and other disease
areas.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
For further general presentation, please visit:
https://ir.aptorumgroup.com/static-files/ca36cc65-6f23-4105-895e-f5f234ecca1e
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020.
As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein. Aptorum Group assumes no
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005556/en/
Investor relations Aptorum Group Limited Investor
Relations Department: Tel: +44 020 80929299 Email:
investor.relations@aptorumgroup.com Redchip – Financial
Communications United States Investor relations Dave Gentry
dave@redchip.com +1 407 491 4498 Actifin – Financial Communications
Europe Investor relations Ghislaine Gasparetto
ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024